Company
Who we are
Alvotech is a privately owned biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets. We are specialists in biotechnology all working towards a common goal ...
Research and development
WHAT WE DO
Our vision as a company is to build a leading global biopharmaceutical company, while focusing on the development, and the commercialization of medicines for the treatment of severe, immune, inflammatory conditions.
Newsroom
Mark Levick appointed CEO of Alvotech
Alvotech today announced the appointment of Mark Levick as Chief Executive Officer, effective 5 August 2019. Mark brings over 18 years of global industry experience, with a very impressive track record of value creation and success in bringing new biosimilars to market. Prior to joining Alvotech, Mark was the head of development of Sandoz biopharmaceuticals. He succeeds Rasmus Rojkjaer, who has stepped down from his role.
Meet management
World Class team
Our organizational structure is effective, flexible and has a proven track record that will enable the company to bring new biopharmaceutical products quickly and safely to market. The leadership team is helmed by Rasmus Rojkjaer.
Partnerships
Partnering with Alvotech is gaining access to high quality, ready to market biosimilars